Treatment of Functional Popliteal Artery Entrapment Syndrome with Ultrasound-Guided Botox Injection
Popliteal artery entrapment syndrome is an uncommon and underreported cause of lower limb claudication. In the absence of appropriate treatment, it increases the risk of limb ischemia, popliteal artery damage, and embolization. Two subtypes include functional popliteal artery entrapment syndrome (FPAES) and the anatomic subtype (1). The functional subtype is more common and particularly prevalent in young active athletic women (2). Given the rare incidence of FPAES as a cause for limb claudication, it continues to be an imaging and clinical diagnostic challenge. (Source: Journal of Vascular and Interventional Radiology : JVIR)
Source: Journal of Vascular and Interventional Radiology : JVIR - November 29, 2018 Category: Radiology Authors: Aman Wadhwani, Mark Nutley, Darshan Bakshi, Anirudh Mirakhur Tags: Letter to the Editor Source Type: research

EMG in piriformis syndrome diagnosis: Reliability of peroneal H-reflex according to results obtained after surgery, Botox injection and medical treatment
Publication date: Available online 28 November 2018Source: Journal of Clinical NeuroscienceAuthor(s): Hassan Najdi, Dany Mouarbes, Joe Abi-akl, Soha Karnib, Ali Hassan Chamsedine, Roger JawishAbstractDiagnosing piriformis syndrome (PS) throughout the past decades was not that easy, however peroneal H-reflex was proved as reliable test for PS with the change in wave amplitude and delay in conduction as parameters for diagnosis. We interpreted these parameters according to treatment’s results carried out for patients presenting clinical PS, aiming to define a threshold value for peroneal H-reflex delay to accurately di...
Source: Journal of Clinical Neuroscience - November 28, 2018 Category: Neuroscience Source Type: research

Masseter muscle atrophy impairs bone quality of the mandibular condyle but not the alveolar process early after induction
This study aimed to evaluate the bone quality of both the mandibular condyle and alveolar process in the mandible of adult mice during the early stage of a BoNTA ‐induced masseter muscle atrophy, using a combined 3D histomorphometrics and shape analysis approach.MethodsAdult BALB/c mice were divided into an untreated control group and an experimental group; the latter received one single BoNTA injection in the right masseter (BoNTA ‐right) and saline in the left masseter (Saline‐left). 3D bone microstructural changes in the mandibular condyle and alveolar process were determined with high‐resolution microtomography...
Source: Journal of Oral Rehabilitation - November 23, 2018 Category: Dentistry Authors: Juli án Balanta‐Melo, María Angélica Torres‐Quintana, Maximilian Bemmann, Carolina Vega, Constanza González, Kornelius Kupczik, Viviana Toro‐Ibacache, Sonja Buvinic Tags: Original Article Source Type: research

Osteoblasts Regulate Angiogenesis in Response to Mechanical Unloading
AbstractDuring mechanical  unloading, endothelial cells reduce osteogenesis and increase bone resorption. Here we describe the feedback response of endothelial cells to unloaded osteoblasts. Primary endothelial cells, ex vivo mouse aortic rings and chicken egg yolk membranes were incubated with conditioned medium from mouse primary osteoblasts (OB-CM) subjected to unit gravity or simulated microgravity, to assess its effect on angiogenesis. In vivo injection of botulin toxin A (Botox) in the quadriceps and calf muscles of C57BL/6J mice was performed to mimic disuse osteoporosis. Unloaded osteoblasts showed strong upre...
Source: Calcified Tissue International - November 21, 2018 Category: Orthopaedics Source Type: research

Efficacy and Safety of Botulinum Toxin Type A in Spasticity Caused by Spinal Cord Injury: A Randomized, Controlled Trial.
The objective of this study was to compare the efficacy and safety of botulinum toxin type A versus baclofen in spasticity. MATERIAL AND METHODS A total of 336 patients who had spasticity caused by spinal cord injury were enrolled in a randomized (in 1: 1: 1: ratio) for placebo, controlled trial. Patients had received baclofen (BA group, n=112), local intramuscular injection of 500 U Botulinum toxin type A (BTI group, n=112), or physical therapies alone (placebo group, n=112). Modified Ashworth scale (mAS) score, disability assessment scale (DAS) score, modified medical research council (mMRC) score, the Barthel Index (BI)...
Source: Medical Science Monitor - November 14, 2018 Category: Research Tags: Med Sci Monit Source Type: research

Treatment of anal fissure: a survey of surgical practice in Australia and New Zealand
ConclusionWhile areas of consensus mostly agreed with guideline recommendations, there remain many areas of community equipoise some of which warrant further research.This article is protected by copyright. All rights reserved. (Source: Colorectal Disease)
Source: Colorectal Disease - November 9, 2018 Category: Gastroenterology Authors: Javariah Siddiqui, George E Fowler, Assad Zahid, Kilian Brown, Christopher J Young Tags: Original Article Source Type: research

Temporary autonomic modulation with botulinum toxin type A to reduce atrial fibrillation after cardiac surgery
Postoperative atrial fibrillation (POAF) frequently complicates cardiac surgery and is associated with worse outcomes. The cardiac autonomic nervous system is implicated in the pathogenesis of POAF. (Source: Heart Rhythm)
Source: Heart Rhythm - November 6, 2018 Category: Cardiology Authors: Nathan H. Waldron, Mary Cooter, John C. Haney, Jacob N. Schroder, Jeffrey G. Gaca, Shu S. Lin, Martin I. Sigurdsson, Marat Fudim, Mihai V. Podgoreanu, Mark Stafford-Smith, Carmelo A. Milano, Jonathan P. Piccini, Joseph P. Mathew Source Type: research

The Role of Botox in Colorectal Disorders
AbstractPurpose of reviewTo overview the current medical literature on the efficacy of botulism toxin treatment (BTX-A) for lower gastrointestinal disorders (GIT).Recent findingsBTX-A was found to have a short-term efficacy for the treatment of dyssynergic defecation. Surgical treatment was found to be more effective than BTX-A for the healing of chronic anal fissures, and BTX-A can be considered when surgery is undesirable. Data regarding the effects of BTX-A injection for the treatment of chronic anal pain is limited. Beneficial effects were observed only in a minority of patients. BTX-A treatment was found to be effecti...
Source: Current Treatment Options in Gastroenterology - November 5, 2018 Category: Gastroenterology Source Type: research

Response to “Comment on: Botulinum Toxin Type A Overdoses: Analysis of the FDA Adverse Event Reporting System Database”
(Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - November 3, 2018 Category: Drugs & Pharmacology Source Type: research

Comment on: Botulinum Toxin Type A Overdoses: Analysis of the FDA Adverse Event Reporting System Database
(Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - November 3, 2018 Category: Drugs & Pharmacology Source Type: research

Glabellar Botulinum Toxin Injections in Major Depressive Disorder: A Critical Review.
Conclusions: In general, the results from the reviewed studies suggest that BTA may be a promising treatment for MDD. However, these findings need to be interpreted with caution due to several limitations of the reviewed studies such as lack of a priori hypotheses, limited sample sizes, large gender bias, and significant difficulty in ensuring blinding. PMID: 30326186 [PubMed - in process] (Source: The Primary Care Companion for CNS Disorders)
Source: The Primary Care Companion for CNS Disorders - October 18, 2018 Category: Primary Care Tags: Prim Care Companion CNS Disord Source Type: research

Expression of pituitary adenylate cyclase-activating peptide, calcitonin gene-related peptide and headache targets in the trigeminal ganglia of rats and humans
Publication date: Available online 15 October 2018Source: NeuroscienceAuthor(s): Simona Denise Frederiksen, Karin Warfvinge, Lena Ohlsson, Lars EdvinssonAbstractNeurotransmitter and headache target localization in the trigeminal ganglia (TG) might increase the understanding of sites of action, and mechanisms related to headache therapy. The overall aim of the study was to investigate the presence of migraine targets in the TG with particular emphasis on pituitary adenylate cyclase-activating peptide (PACAP) and calcitonin gene-related peptide (CGRP), known to be involved in cranial pain processing, and selected headache ta...
Source: Neuroscience - October 16, 2018 Category: Neuroscience Source Type: research

Review: In trigeminal neuralgia, carbamazepine, botulinum toxin type A, or lidocaine improve response rate vs placebo.
PMID: 30326087 [PubMed - in process] (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - October 16, 2018 Category: Internal Medicine Authors: Steinberg DI Tags: Ann Intern Med Source Type: research

One-Year Relapse of Mandibular Distraction for Hemifacial Microsomia Using Masseteric Botulinum Toxin Type A Injections
Conclusions: The combination of DO, orthognathic surgeries, autologous fat particle transplantation, and masseter muscle type A botulinum toxin injection technique could be a comprehensive treatment plan for adult patients of HFM. Furthermore, masseter injection of type A botulinum toxin might be an alternative method to reduce the early recurrence rate of postoperative adult patients of HFM. (Source: Journal of Craniofacial Surgery)
Source: Journal of Craniofacial Surgery - October 1, 2018 Category: Surgery Tags: Original Articles Source Type: research

What Is the True Catheterization Rate After Intravesical OnabotulinumtoxinA Injection?
(Abstracted from Int Urogynecol J 2018;29:1005–1009) Intravesical onabotulinumtoxinA (Botox) is widely used for the treatment of urinary urge incontinence and overactive bladder (OAB). One of the most common complications of intravesical onabotulinumtoxinA injection is incomplete bladder emptying requiring clean intermittent catheterization (CIC). (Source: Obstetrical and Gynecological Survey)
Source: Obstetrical and Gynecological Survey - October 1, 2018 Category: OBGYN Tags: GYNECOLOGY: UROGYNECOLOGY Source Type: research

Complications in Minimally Invasive Facial Cosmetic Surgery
Minimally invasive facial cosmetic surgery procedures have seen an increase in numbers over the past decade. The 2 most common procedures are Botulinum toxin type A injection and soft-tissue fillers. In fact, the number one non-invasive surgical procedure was neuromodulator injection with 4 597 886 procedures in 2016 and second being hyaluronic acid with 2 494 814 in 2016. Although soft-tissue fillers have a high-safety profile, these materials have been recently associated with serious and irreversible complications. (Source: Journal of Oral and Maxillofacial Surgery)
Source: Journal of Oral and Maxillofacial Surgery - October 1, 2018 Category: ENT & OMF Authors: S. Halepas, D. Weyman, E.M. Ferneini Tags: Poster Session: Cosmetic Surgery/Orthognathic Surgery Source Type: research

The Use of Battlefield Acupuncture Prior to Botulinum Toxin A Administration: A 2-Patient Case Series.
Conclusions: BFA is a safe and effective treatment option for rapid pain reduction, enabling Botulinum toxin A to be administered more easily to patients who have had pain or anxiety during prior injections. PMID: 30377465 [PubMed] (Source: Acupuncture in Medicine)
Source: Acupuncture in Medicine - October 1, 2018 Category: Complementary Medicine Authors: Shao X, Corcoran M, O'Bryan M Tags: Med Acupunct Source Type: research

Protective Effect of Blepharospasm on the Anterior Segment of the Eye.
In conclusion, comparison of the results between the two groups of patients may implicate that advanced blepharospasm has a protective effect on ocular surface. PMID: 30256021 [PubMed - in process] (Source: Acta Clinica Croatica)
Source: Acta Clinica Croatica - September 27, 2018 Category: General Medicine Tags: Acta Clin Croat Source Type: research

Botulinum Toxin as a Treatment for Refractory Gastroparesis: a Literature Review
AbstractPurpose of reviewGastroparesis (GP) is a disorder of gastrointestinal motility which leads to delayed gastric emptying in the absence of mechanical obstruction. Treatment is limited as many patients are refractory to dietary modification and the use prokinetic medications carry significant adverse risks. These limitations necessitate more research into experimental therapies. The purpose of this article is to summarize the known information and guidelines on the diagnosis and management of GP and to review the latest literature on experimental treatments.Recent findingsBased on the current available literature, the...
Source: Current Treatment Options in Gastroenterology - September 26, 2018 Category: Gastroenterology Source Type: research

Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3  years of treatment
AbstractBackgroundEvidence on whether the therapeutic effect and good safety profile of onabotulinumtoxinA (Botox ®) in chronic migraine (CM) patients is maintained over long term treatment is still limited. We herein aimed at assessing whether there is a sustained benefit and good safety with repeated onabotulinumtoxinA sessions in CM over more than three years of treatment.MethodsWe prospectively enrolled 65 CM patients, who were classified as responders after three sessions of onabotulinumtoxinA and were eligible to further continue treatment. Data documenting longitudinal changes from the trimester after the third ...
Source: The Journal of Headache and Pain - September 17, 2018 Category: Neurology Source Type: research

Optimal surgical intervention for achalasia: laparoscopic or robotic approach
AbstractLaparoscopic esophageal myotomy is the standard surgical intervention for achalasia. Compared to standard laparoscopic techniques, use of the robot has theoretical advantages of improved visualization and dexterity. We evaluated the University of Arizona ’s experience with the two alternatives to compare outcomes. Patients who underwent either laparoscopic or robot-assisted myotomy were identified from a retrospective database from 1/1/2006 to 12/31/2015. Patient demographics, prior treatment, intra-operative complications, operative time, post-op erative length of stay and complications, and long-term result...
Source: Journal of Robotic Surgery - September 14, 2018 Category: Surgery Source Type: research

CT-Guided Chemical Thoracic Sympathectomy versus Botulinum Toxin Type A Injection for Palmar Hyperhidrosis
Thorac cardiovasc Surg DOI: 10.1055/s-0038-1668599 Background The present study aimed to evaluate and compare the efficacy of botulinum toxin type A (BTX-A) injection versus thoracic sympathectomy for idiopathic palmar hyperhidrosis. Methods Fifty-one patients with idiopathic palmar hyperhidrosis were treated with either BTX-A injection or thoracic sympathectomy between March 2013 and April 2016. The severity of palmar hyperhidrosis was qualitatively measured via the Hyperhidrosis Disease Severity Scale (HDSS). All patients completed a questionnaire that detailed the time taken for the treatment to work, lo...
Source: The Thoracic and Cardiovascular Surgeon - September 14, 2018 Category: Cardiovascular & Thoracic Surgery Authors: Yang, HongJun Kang, Jianjie Zhang, Shufen Peng, Kairun Deng, Bingmei Cheng, Biao Tags: Original Thoracic Source Type: research

CT-Guided Chemical Thoracic Sympathectomy versus Botulinum Toxin Type A Injection for Palmar Hyperhidrosis.
Abstract BACKGROUND:  The present study aimed to evaluate and compare the efficacy of botulinum toxin type A (BTX-A) injection versus thoracic sympathectomy for idiopathic palmar hyperhidrosis. METHODS:  Fifty-one patients with idiopathic palmar hyperhidrosis were treated with either BTX-A injection or thoracic sympathectomy between March 2013 and April 2016. The severity of palmar hyperhidrosis was qualitatively measured via the Hyperhidrosis Disease Severity Scale (HDSS). All patients completed a questionnaire that detailed the time taken for the treatment to work, local or systemic adverse effect...
Source: The Thoracic and Cardiovascular Surgeon - September 14, 2018 Category: Cardiovascular & Thoracic Surgery Authors: Yang H, Kang J, Zhang S, Peng K, Deng B, Cheng B Tags: Thorac Cardiovasc Surg Source Type: research

Optimal surgical intervention for achalasia: laparoscopic or robotic approach
AbstractLaparoscopic esophageal myotomy is the standard surgical intervention for achalasia. Compared to standard laparoscopic techniques, use of the robot has theoretical advantages of improved visualization and dexterity. We evaluated the University of Arizona ’s experience with the two alternatives to compare outcomes. Patients who underwent either laparoscopic or robot-assisted myotomy were identified from a retrospective database from 1/1/2006 to 12/31/2015. Patient demographics, prior treatment, intra-operative complications, operative time, post-op erative length of stay and complications, and long-term result...
Source: Journal of Robotic Surgery - September 14, 2018 Category: Surgery Source Type: research

Blepharospasm with elevated anti-acetylcholine receptor antibody titer
Conclusion: Patients with BSP had an eleva ted anti-AChR Abs titer, which suggests that dysimmunity plays a role in the onset of BSP. An increased anti-AChR Abs titer may be a predictor for poor response to BoNT-A in BSP.RESUMO Objetivo: Determinar se os n íveis séricos do anticorpo antirreceptor de acetilcolina (anti-AChR-Abs) estão relacionados aos parâmetros clínicos do blefaroespasmo (BSP). Métodos: Fora recrutados 83 adultos com BSP, 60 pacientes ambulatoriais com espasmo hemifacial (HFS) e 58 controles. Foi aplicado um questionário para registrar história pessoal...
Source: Arquivos de Neuro-Psiquiatria - September 14, 2018 Category: Neurology Source Type: research

Safety Profile of High-Dose Botulinum Toxin Type A in Post-Stroke Spasticity Treatment
AbstractBotulinum toxin type A (BoNT-A) is considered the gold standard for the treatment of focal post-stroke spasticity (PSS). However, a recently published study estimated that a significant percentage of patients affected by PSS could benefit from higher doses of BoNT-A than those permitted by current directives in the countries studied. Several studies have reported the use of high doses of BoNT-A in the management of patients affected by severe PSS; however, the most important adverse effect of this drug might be systemic diffusion of the toxin, which could potentially be related to its dose. Even if systemic toxicit...
Source: Clinical Drug Investigation - September 12, 2018 Category: Drugs & Pharmacology Source Type: research

Botulinum Toxin Type-A as an alternative treatment for gummy smile: a case report.
This article presents a case of a woman with excessive gingival exhibition during the smile related to vertical maxillary excess and hyperactive upper lip elevator muscles. This patient was treated using botulinum toxin type A (BT) to camouflage the deformity and improve her facial aesthetic. This therapeutic option proved to be effective and should be a good alternative for patients. (Source: Dermatology Online Journal)
Source: Dermatology Online Journal - September 12, 2018 Category: Dermatology Source Type: research

A pilot study comparing the efficacy of two formulations of botulinum toxin type A for muscular calves contouring
Journal of Cosmetic Dermatology, EarlyView. (Source: Journal of Cosmetic Dermatology)
Source: Journal of Cosmetic Dermatology - September 11, 2018 Category: Dermatology Authors: Rungsima Wanitphakdeedecha MD, MA, MSc , Chanida Ungaksornpairote MD , Arisa Kaewkes MD , Angkana Sathaworawong MD , Bavornrat Vanadurongwan MD , Nittaya Lektrakul MD Source Type: research

Efficacy and Safety of Botulinum Toxin Type A Injection in Patients with Bilateral Trapezius Hypertrophy
ConclusionA single injection of BTxA for aesthetic reconstruction of the upper trapezius is safe and effective in patients with bilateral trapezius hypertrophy.Level of Evidence IVThis journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authorswww.springer.com/00266. (Source: Aesthetic Plastic Surgery)
Source: Aesthetic Plastic Surgery - September 11, 2018 Category: Cosmetic Surgery Source Type: research

Complications of Botox and their Management
AbstractPurpose of ReviewAdherence to anticholinergic medications is known to be a problem in patients with overactive bladder, with only 13.2% of patients continuing anticholinergic therapy beyond 1  year D’Souza et al. (J Manag Care Pharm. 14:291-301, 2008).Recent FindingsPrior to the advent of third line therapies such as onabotulinumtoxin A, refractory overactive bladder (OAB) was managed with augmentation cystoplasty, a lengthy surgery with associated side effects including lifetime need for self-catheterization, ileus, and metabolic disturbances. The advent of onabotulinumtoxin A has drastically reduced th...
Source: Current Urology Reports - September 7, 2018 Category: Urology & Nephrology Source Type: research

Congenital myasthenic syndromes and myasthenia
Botulinum toxin type A (BTA) is widely used for both medical treatment and cosmetic purposes. Botulinum toxin type A is a potent neurotoxin and produced by the anaerobic bacterium Clostridium botulinum: It paralyzes the injected muscle by inhibiting acetylcholine release from synapses of neuromuscular junctions and consequently, a dose dependent, reversible denervation develops in muscles. With increasing numbers of people receiving cosmetic botulinum toxin, we should consider the side effects of botulinum toxin type A carefully. (Source: Neuromuscular Disorders)
Source: Neuromuscular Disorders - September 6, 2018 Category: Neurology Authors: J. So, S. Ho, D. Bae Source Type: research

Botulinum toxin type A use by breastfeeding mothers
Publication date: September 2018Source: Reproductive Toxicology, Volume 80Author(s): Delwyn J. Cupitt, Debra S. Kennedy (Source: Reproductive Toxicology)
Source: Reproductive Toxicology - September 5, 2018 Category: Toxicology Source Type: research

Comparison of efficacy and toxicity between botulinum toxin subtypes A1 and A2 in cynomolgus macaques.
This study suggested that A2NTX products are more suitable for the treatment of neurological disorders. PMID: 30193802 [PubMed - as supplied by publisher] (Source: Toxicon)
Source: Toxicon - September 4, 2018 Category: Toxicology Authors: Torii Y, Sasaki M, Shin MC, Akaike N, Kaji R Tags: Toxicon Source Type: research

Cost-Effectiveness of Third-Line Therapies for Overactive Bladder
AbstractPurpose of ReviewWhile third-line therapies for overactive bladder and urgency urinary incontinence are well-described in guideline statements, there is little offered in guidance when it comes to selecting a particular intervention amongst these therapies for patients. Data regarding efficacy has a body of literature that takes sides on all fronts, making efficacy of these interventions a topic of continued debate. An ever-present factor for consideration also remains —cost of therapy. This review examines current data available for cost of third-line therapies.Recent FindingsIn this body of literature regar...
Source: Current Bladder Dysfunction Reports - September 1, 2018 Category: Urology & Nephrology Source Type: research

The Effects of Botulinum Toxin Injections on Plantar Flexor Spasticity in Different Phases After Stroke: A Secondary Analysis From a Double-Blind, Randomized Trial
Publication date: August 2018Source: PM&R, Volume 10, Issue 8Author(s): Hyun-Mi Oh, Geun-Young Park, Young Min Choi, Hyung Jung Koo, Yongjun Jang, Sun ImAbstractBackgroundThere are no guidelines on the ideal time to inject botulinum toxin type A (BT-A) for lower leg spasticity in stroke patients. An early injection may produce unwanted weakness, interfering with gait recovery.ObjectiveTo evaluate whether the outcomes after BT-A injection for plantarflexion spasticity can be different according to stroke chronicity.DesignA secondary analysis study from a double-blinded, randomized trial with group reclassification accor...
Source: PMandR - August 21, 2018 Category: Rehabilitation Source Type: research

EUS-Guided Intragastric Injection of Botulinum Toxin A in the Preoperative Treatment of Super-Obese Patients: a Randomized Clinical Trial
The objective of this prospective, double-blind, single-center randomized study was to evaluate the effects of endoscopic ultrasound-guided intragastric BTX-A injections, as a bridge to bariatric surgery, in super-obese patients.MethodsThirty-two super-obese patients were randomized to one of two groups: BTX-A, in which 200  units of BTX-A were injected into the gastric antrum and body; and control, in which the same injections were performed with 0.9% saline. Weight, body mass index (BMI), and loss of excess weight were measured monthly over a 6-month period. Gastric emptying scintigraphy was performed before and aft...
Source: Obesity Surgery - August 17, 2018 Category: Surgery Source Type: research

Contemporary Treatment of Detrusor Sphincter Dyssynergia: a Systematic Review
AbstractPurpose of ReviewTo systematically review the literature to determine outcomes of detrusor sphincter dyssynergia (DSD) treatments. DSD can present in patients with neurogenic bladder due to a variety of conditions, but no treatment guidelines currently exist. Ovid Medline, Embase, PubMed, and Web of Science were searched within the last 10  years for “detrusor sphincter dyssynergia.” Results were independently reviewed by two coauthors for inclusion using the Preferred Reporting Items for Systematic Reviews and Meta-analysis Protocols (PRISMA) guidelines. Exclusion criteria were pediatric populatio...
Source: Current Bladder Dysfunction Reports - August 15, 2018 Category: Urology & Nephrology Source Type: research

Botulinum toxin type A or selective neurotomy for treating focal spastic muscle overactivity?
ConclusionBotulinum toxin type A has the highest level of evidence and the largest range of indications. However, the botulinum toxin effect is reversible and seems less effective, which supports a permanent surgical treatment such as selective neurotomy, especially for the spastic foot. Further research is needed to compare the effect of botulinum toxin type A and selective neurotomy for the different types of spastic muscle overactivity and clinical patterns. (Source: Annals of Physical and Rehabilitation Medicine)
Source: Annals of Physical and Rehabilitation Medicine - August 12, 2018 Category: Rehabilitation Source Type: research

Botulinum toxin injection and tear production
Purpose of review In 1980, botulinum toxin type A (BTX-A) was introduced for the treatment of strabismus and benign essential blepharospasm. Since then, a number of additional indications have been introduced, which continue to expand, providing less invasive solutions in managing different ophthalmic conditions. Recent findings Successful trials of BTX-A injection into the lacrimal gland have been reported for the treatment of epiphora caused by primary lacrimal gland hyperlacrimation, functional tearing, gustatory tearing, and lacrimal outflow obstruction. This is achieved through blockage of the cholinergic recepto...
Source: Current Opinion in Ophthalmology - August 10, 2018 Category: Opthalmology Tags: OCULOPLASTIC AND ORBITAL SURGERY: Edited by Richard C. Allen Source Type: research

What is the ideal antibiotic prophylaxis for intravesically administered Botox injection? A comparison of two different regimens
ConclusionsWe found a significantly lower rate of UTIs when patients received a 3-day course of a fluoroquinolone orally as opposed to a single dose of a third-generation cephalosporin IM. Patients with a positive preprocedure culture might benefit from an even longer duration of antibiotics at the time of Botox ® injection. (Source: International Urogynecology Journal)
Source: International Urogynecology Journal - August 3, 2018 Category: OBGYN Source Type: research

6143 —Botulinum toxin type A treatment for Raynaud’s phenomenon: Experience and 3-year follow-up
Introduction: Raynaud ’s phenomenon consists of vasospastic disease of the digital arteries after exposure to cold or stress and may appear in isolation or in the context of a systemic disease. When severe, it causes an important reduction in a patient’s quality of life. The available treatments do not always offer g ood results, making it necessary to look for therapeutic alternatives. (Source: Journal of the American Academy of Dermatology)
Source: Journal of the American Academy of Dermatology - August 2, 2018 Category: Dermatology Source Type: research

Botulinum toxin type A for the treatment of localized recalcitrant chronic pruritus
Background: Chronic pruritus is a common condition that carries a significant burden of disease and can be localized to certain body regions, such as in lichen simplex chronicus, post-burn pruritus, and multiple forms of neuropathic itch. (Source: Journal of the American Academy of Dermatology)
Source: Journal of the American Academy of Dermatology - August 2, 2018 Category: Dermatology Source Type: research

Subject satisfaction demonstrated for two on-label injection volumes of abobotulinumtoxinA when used to treat moderate to severe glabellar lines
In this study, we evaluated both on-label injection volumes in subjects with moderate to severe GLs at maximum frown and asked them to complete questionnaires before and after treatment to assess treatment satisfaction and health-related quality of life subject-reported outcomes, which is the focus of this report. (Source: Journal of the American Academy of Dermatology)
Source: Journal of the American Academy of Dermatology - August 2, 2018 Category: Dermatology Source Type: research

Two phase 3, randomized, double-blind, placebo-controlled, multicenter trials to evaluate the efficacy and safety of daxibotulinumtoxinA for injection to treat moderate to severe glabellar lines (SAKURA 1 and 2)
Objective and purpose: Injectable daxibotulinumtoxinA (RT002; investigational) is a purified 150 kDa botulinum toxin type A devoid of accessory proteins in a lyophilized powder containing a proprietary peptide. Phase 2 data (BELMONT study) show that 40 U daxibotulinumtoxinA is associated with a greater response rate and a significantly longer duration of response (median 23.6 weeks) compared with 20 U onabotulinumtoxinA, as well as a favorable risk-benefit profile (ClinicalTrials.gov NCT02303002). (Source: Journal of the American Academy of Dermatology)
Source: Journal of the American Academy of Dermatology - August 2, 2018 Category: Dermatology Source Type: research

An Algorithm Using Botox Injections for Facial Scar Improvement in Fitzpatrick Type IV–VI Skin
Source: Plastic and Reconstructive Surgery Global Open - August 1, 2018 Category: Cosmetic Surgery Tags: Original Article Source Type: research

S093: pneumatic balloon dilation for palliation of recurrent symptoms of achalasia after esophagomyotomy
ConclusionSerial PBD is safe and effective in treatment of recurrent symptoms of achalasia after esophagomyotomy. (Source: Surgical Endoscopy)
Source: Surgical Endoscopy - July 31, 2018 Category: Surgery Source Type: research

Effect of botulinum toxin type A on the healing of facial skin biopsies - series of cases
Abstract: Several reports have demonstrated difficulties and lack of agreement in the histopathological diagnosis of particular melanocytic lesions, with problems in their management. A histogenetic approach to the study of these lesions originated the following classification: 1. superficial atypical proliferation significance; 2. melanocytic tumor of uncertain potential; 3. pigmented epithelioid melanocitoma of uncertain potential; 4. microinvasive radial growth phase of uncertain potential. The terminology remains controversial, reflecting the uncertainty of the diagnosis and the biological potential of these atypical m...
Source: Anais Brasileiros de Dermatologia - July 30, 2018 Category: Dermatology Source Type: research